Classification

Orange Expands Partnership With Google Cloud to Use AI and GenAI Across Workstreams and Geographies With New Solutions, Closer to Operations

Retrieved on: 
Tuesday, April 9, 2024
Cloud, Automation, GDC, Environment, Customer experience, Intelligence, Partnership, Classification, AI, Root cause analysis, LAS

Through the use of Google Distributed Cloud, Orange can meet local requirements for cloud environments, accelerate AI adoption and benefits for customers, and foster an open and value-driven approach.

Key Points: 
  • Through the use of Google Distributed Cloud, Orange can meet local requirements for cloud environments, accelerate AI adoption and benefits for customers, and foster an open and value-driven approach.
  • Designed with AI and data-intensive workloads in mind, GDC will enable Orange to take a pivotal step towards accelerating AI adoption into its operations across the 26 countries it serves.
  • Operational Efficiency: Orange will be able to run gen AI models on-premise in an environment that is very elegantly integrated into similar Vertex AI services on Google Cloud.
  • Over the last three years, Orange has migrated 13 petabytes of data to Google Cloud and has many strategic use cases in production across ten countries running on Google Cloud.

EDD Changes Procedures to Collect from Disputed Audit Findings: Urgent Action Required for Affected Individuals and Businesses

Retrieved on: 
Tuesday, April 9, 2024
Failure, IRS, Documentation, SBA, SAN, AB-5, Classification, CUIAB, NOA, EDD, Multimedia, Collection, Government, Medical device

CA EDD introduces significant procedural changes affecting individuals and businesses subject to audit assessments.

Key Points: 
  • CA EDD introduces significant procedural changes affecting individuals and businesses subject to audit assessments.
  • John Milikowsky, founder of Milikowsky Tax Law , emphasizes the importance of understanding the revised procedures and taking appropriate action promptly.
  • To further safeguard their rights, affected individuals and businesses are urged to immediately contact the Taxpayer Advocate Service for EDD at 866-594-4177.
  • For immediate assistance and guidance on navigating EDD audit procedures, individuals and businesses are encouraged to reach out to Milikowsky Tax Law.

Quarterhill Announces Closing of Red Fox Acquisition

Retrieved on: 
Monday, April 8, 2024
Intelligent transportation system, Classification, Red, Acquisition, Software, Quantum, Adjustment, TSX, Lidar, Red fox

TORONTO, April 8, 2024 /PRNewswire/ - Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), a leading provider of tolling and enforcement solutions in the Intelligent Transportation System ("ITS") industry, announces that it has completed the previously announced acquisition of Red Fox I.D.

Key Points: 
  • TORONTO, April 8, 2024 /PRNewswire/ - Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), a leading provider of tolling and enforcement solutions in the Intelligent Transportation System ("ITS") industry, announces that it has completed the previously announced acquisition of Red Fox I.D.
  • Limited ("Red Fox").
  • Based in Haddenham, England, Red Fox is a profitable and growing provider of Automatic Vehicle Detection and Classification ("AVDC") software to the tolling industry.
  • "The Red Fox transaction met both our strategic and financial criteria for an acquisition, and we are pleased to welcome their team to Quarterhill," said Chuck Myers, CEO of Quarterhill.

Once More Cognni Revolutionizes Data Mapping and Protection

Retrieved on: 
Friday, April 5, 2024
Data, DLP, Classification, Map, Medical device

TEL-AVIV, Israel, April 5, 2024 /PRNewswire/ -- Cognni Ltd, a leading provider of information intelligence solutions, announced today the launch of its Data At-Rest Discovery and Classification solution.

Key Points: 
  • Data At-Rest Discovery and Classification is a zero-effort solution that leverages Cognni's proprietary AI technology to autonomously scan, map, and classify data stored in databases, files, and cloud services.
  • This solution provides actionable insights and recommendations, as well as assigns sensitivity labels and information types to each data element, mitigating data risks and ensuring compliance with data privacy regulations.
  • Data At-Rest Discovery and Classification is part of Cognni's Information Intelligence Platform, which also includes Data In-Motion Discovery and Classification, Data Subject Search, and Data Security Posture Dashboards.
  • Cognni integrates seamlessly with Microsoft Purview Information Protection and other DLP vendors to enhance data protection and governance capabilities.

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, March 25, 2024
Tax, Growth, Tufts University, Patient, Extracellular matrix, Classification, Sale, Acquisition, Nature, Adjustment, SMTI, Infection, Depreciation, GAAP, Peptide

Zach Fleming, Sanara's CEO, stated, “During 2023, the Sanara team achieved several key strategic and operational milestones that position the Company for continued strong growth in 2024.

Key Points: 
  • Zach Fleming, Sanara's CEO, stated, “During 2023, the Sanara team achieved several key strategic and operational milestones that position the Company for continued strong growth in 2024.
  • The Company’s products were contracted or approved to be sold in more than 3,000 hospitals/ambulatory surgery centers as of December 31, 2023.
  • In October 2023, Sanara recorded its first sale of ALLOCYTE® Plus, a human cell and tissue-based product.
  • In November 2023, Sanara announced the publication of a retrospective study involving 5,335 patients.

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

Retrieved on: 
Monday, March 25, 2024
Letter, Emergent, Risk, Patient, CGMP, Ethics, Classification, News, EBS, Life, NAI, Emergent BioSolutions, VAI, FDA, Food, Management

GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility.

Key Points: 
  • GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility.
  • Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (cGMP).
  • “We will continue to put quality and compliance first in our manufacturing operations to ensure we’re delivering high quality products to our customers and patients.”
    The result of obtaining NAI status in Bayview is a continuation of Emergent’s strong commitment to quality and compliance.
  • In 2023, Emergent manufacturing facilities were successfully inspected by five regulatory agencies across the globe and five other inspectional bodies for 18 inspections, including three by the FDA that resulted in NAI or VAI status.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of PSQ Holdings, Inc. - PSQH

Retrieved on: 
Saturday, March 23, 2024
Prior, Classification, News, LLP, WalletHub, Security (finance), Business analyst, Bank statement, ASC, Pomerantz, PSQ

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PSQ Holdings, Inc. (“PSQ” or the “Company”) (NYSE: PSQH).

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PSQ Holdings, Inc. (“PSQ” or the “Company”) (NYSE: PSQH).
  • The investigation concerns whether PSQ and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Attention PSQ Holdings, Inc. Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Wednesday, March 20, 2024
Classification, Security (finance), Business analyst, Disclosure, Bank statement, ASC, PSQ, Online shopping

LOS ANGELES, March 20, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises PSQ Holdings, Inc. ("PSQ" or the "Company") (NYSE: PSQH) investors that the law firm has initiated an investigation on behalf of investors that lost money on their PSQ stock. PSQ investors are encouraged to contact the firm to discuss their legal rights.

Key Points: 
  • LOS ANGELES, March 20, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises PSQ Holdings, Inc. ("PSQ" or the "Company") (NYSE: PSQH ) investors that the law firm has initiated an investigation on behalf of investors that lost money on their PSQ stock.
  • PSQ investors are encouraged to contact the firm to discuss their legal rights.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Wednesday, March 20, 2024
Failure, Economy, Brussels Stock Exchange, Exercise, Patient, Risk, European, Intellectual property, Marketing, SCI, Annual, Public, Private, KBC, AFM, Prospectus, Royal Victorian Order, VWAP, ARC, Hand, Acceleration, Part, Research, Classification, Enrollment, Certification, DSM-IV codes, CSO, FDA, Movement, Engineering, EUR, Private placement, BCI, Offerings, Public offering, Market, Issue, Euronext Amsterdam, Probability, Security (finance)

The Issue Price will be determined by the accelerated book-building initiated with institutional investors.

Key Points: 
  • The Issue Price will be determined by the accelerated book-building initiated with institutional investors.
  • The Public Offering will not extent to retail investors located outside of France.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • It is the Company’s intention to raise gross proceeds of approximately €15.0 million from the Offerings, with an up to €5 million upsize option.

Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q

Retrieved on: 
Wednesday, March 20, 2024
CDMO, Rule, Notice, Classification, Security (finance), Bank statement, Debt-to-GDP ratio, Calendar, Cryptocurrency

The Rule requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”).

Key Points: 
  • The Rule requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”).
  • Under Nasdaq rules, the company has 60 calendar days from the receipt of the Notice, or until May 20, 2024, to submit a plan to regain compliance with the Rule.
  • The company intends to file the Form 10-Q as promptly as reasonably practicable.
  • If the company does not file the Form 10-Q by May 20, 2024, the company intends to timely submit a plan to regain compliance with the Rule.